Generic Norliqva Availability
Last updated on Jan 8, 2025.
Norliqva is a brand name of amlodipine, approved by the FDA in the following formulation(s):
NORLIQVA (amlodipine besylate - solution;oral)
-
Manufacturer: CMP DEV LLC
Approval date: February 24, 2022
Strength(s): EQ 1MG BASE/ML [RLD]
Has a generic version of Norliqva been approved?
No. There is currently no therapeutically equivalent version of Norliqva available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Norliqva. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Pharmaceutical solution of amlodipine
Patent 11,253,474
Issued: February 22, 2022
Inventor(s): Mandal Jayanta Kumar & Patel Malay & Nagar Swati & DeHart Michael Paul
Assignee(s): LIQMEDS WORLDWIDE LIMITEDDisclosed herein is a liquid pharmaceutical formulation substantially free of water, comprising: (i) amlodipine or a pharmaceutically acceptable salt thereof, (ii) at least one pharmaceutically acceptable excipient, and (iii) a sufficient amount of a vehicle comprising glycerin. Also disclosed herein is a liquid pharmaceutical formulation substantially free of water and ethanol, comprising: (i) amlodipine or a pharmaceutically acceptable salt thereof, (ii) at least one pharmaceutically acceptable excipient, and (iii) a sufficient amount of a vehicle comprising glycerin.
Patent expiration dates:
- February 24, 2041✓✓
- February 24, 2041✓✓
- February 24, 2041✓✓
- February 24, 2041
-
Patent 11,458,095
Patent expiration dates:
- February 24, 2041✓✓
- February 24, 2041✓✓
- February 24, 2041✓✓
- February 24, 2041
-
Patent 11,723,866
Patent expiration dates:
- February 24, 2041✓✓
- February 24, 2041✓✓
- February 24, 2041✓✓
- February 24, 2041
-
Patent 12,005,141
Patent expiration dates:
- February 24, 2041✓✓
- February 24, 2041✓✓
- February 24, 2041
More about Norliqva (amlodipine)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- Drug class: calcium channel blockers
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
